Working… Menu

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02920996
Recruitment Status : Recruiting
First Posted : September 30, 2016
Last Update Posted : August 5, 2019
Eli Lilly and Company
Information provided by (Responsible Party):
Mark Awad, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : March 2024